Tech Company Financing Transactions
Oxagen Limited Funding Round
MPM Capital, 3i Venture Capital and Abingworth participated in a $59.8 million Series B venture round for Oxagen Limited. The round closed on 5/23/2005.
Transaction Overview
Company Name
Announced On
5/23/2005
Transaction Type
Venture Equity
Amount
$59,800,000
Round
Series B
Investors
MPM Capital (Lead Investor) (Luke Evnin)
Proceeds Purpose
The proceeds of the funding will be used to advance Oxagen's lead programme, a novel small molecule anti-inflammatory for asthma to the clinic and to expand the company's clinical and pre-clinical stage portfolio.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
265 Strand
London, WC2R 1BH
UK
London, WC2R 1BH
UK
Phone
Website
Email Address
Overview
Oxagen is a biopharmaceutical company building a novel drug pipeline with a focus on the GPCR family.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Timothy Edwards
Browse more venture capital transactions:
Prev: 5/20/2005: AGIS Network venture capital transaction
Next: 5/23/2005: TriActive venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs